Guidehouse Launches The Tech Guide 2025
Global professional services firm publishes a roadmap for businesses and government agencies seeking to maximize AI and other critical technologies
MCLEAN, Va., June 24, 2025 /PRNewswire/ — In an era when disruption is the norm, racing to adopt the latest technology isn't enough—leaders need a plan that's focused on strategy and long-term outcomes. That's a central message conveyed in The Tech Guide, a landmark report published today by Guidehouse, a global AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors.
Designed for senior leaders in both business and government, The Tech Guide 2025: A Roadmap for Turning Urgency into Advantage is meant to empower decision-makers to translate emerging tech into real-world impact. From AI and cloud infrastructure to data platforms and cybersecurity, the Guide contains actionable insights for maximizing the potential of these core technologies, not just to boost efficiency—a priority the Guide emphasizes is now table-stakes—but to create value and lock in competitive advantage.
'At a time when the pace of change is only accelerating, the winners won't be the ones chasing the newest tools—they'll be the ones who know how to use them strategically,' said Stuart Brown, Guidehouse Technology Leader. 'The Tech Guide cuts through the chaos and delivers a clear path to smarter, faster decisions.'
Unlike traditional forecast-focused tech-trend reports, The Tech Guide 2025 is a detailed practical handbook, grounded in up-to-date, real-world insights from senior Guidehouse technology leaders. It's also sector-specific: The Tech Guide gives readers downloadable AI Acceleration Frameworks—concise checklists for fast, safe AI integration for healthcare, energy providers, financial services, and government agencies.
Key takeaways:
AI is the starting line, not the end of the race: Real advantage comes from integrating AI solutions with resilient cloud infrastructure, robust platforms, and well-governed data to create an adaptable, ever-evolving tech model that's future-ready and fit for purpose.
Speed for speed's sake is a risk: The Guide outlines how leaders can avoid common missteps that sacrifice trust and productivity in the name of fast adoption.
Government agencies are poised for a big leap forward: New public-private alliances, growing investment from major tech players, and an iterative approach to AI scaling can empower public-sector entities to move at a commercial pace, safely and responsibly.
The future is agentic: The Tech Guide points the way forward for tech leaders seeking to understand and leverage autonomous AI agents, which are on the cusp of fundamentally transforming workflows and operations in multiple industries.
'The Tech Guide is about helping leaders step back, refocus, and ask the bigger question—not 'what's next?' but 'what matters most?'' said Karen Odegaard, Guidehouse's AI Leader. 'It's not just about adopting faster—it's about transforming smarter.'
The Tech Guide 2025 is now available for download at guidehouse.com/TechGuide.
About Guidehouse
Guidehouse is a global AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors. With an integrated business technology approach, Guidehouse drives efficiency and resilience in the healthcare, financial services, energy, infrastructure, and national security markets. Built to help clients across industries outwit complexity, the firm brings together approximately 18,000 professionals to achieve lasting impact and shape a meaningful future.
Media Contact:
GuidehouseCecile Fradkin cfradkin@scprgroup.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
an hour ago
- The Star
Economists call for structural reforms to shift China's focus to consumption
While eye-catching technological breakthroughs – led by the DeepSeek artificial intelligence (AI) model – have boosted confidence in China amid intensifying rivalry with the United States, economists at the Annual Meeting of the New Champions in Tianjin have called for structural reforms to make China a consumption-driven economy. 'We can talk about technological supremacy, like AI and all these, but China is never going to be a rich country unless it becomes a big consumer country,' Jin Keyu, a professor at Hong Kong University of Science and Technology's school of business and management, said at the World Economic Forum event, which is also known as 'Summer Davos'. China's political economy mechanism is largely geared towards subsidising production to gain competitiveness, Jin said during a panel discussion on Thursday. 'Chinese goods are so competitive, and everyone's importing Chinese goods, then China is going to have a real problem, not just with the US, but with the rest of the world, because it's no longer about just efficiency, it's about harmony,' she said. 'It's about giving other countries an opportunity to be part of the global supply chain in every single sector.' Jin said China should raise its internal consumption to harmonise its trading relationships, with opportunities to be found in the services sector and in the smaller Chinese cities that young people were flocking back to. 'It will be fantastic if the yardstick competition on the local governments can put consumption as one of the measurements of success,' she added. Eswar Prasad, an economics professor at Cornell University in New York, said during the same panel discussion that pushing ahead with deeper structural reforms is a critical issue for the Chinese government. 'The brief surge in confidence that we have seen thanks to the shift in narrative might be difficult to sustain if you don't get the macroeconomics right,' he said. 'So technology is great, but you need macroeconomics to support it. 'Some deeper-rooted structural reforms, which seem to have been taken off the table for now, really need to be brought back on the table. And with that, I think consumers might end up becoming much more confident.' While DeepSeek has increased confidence in China's capital market, it has not had the same effect among young people or in the labour market, said Joseph Luc Ngai, Greater China chairman at management consultancy McKinsey & Company. 'In fact, DeepSeek has created some anxiety around 'hey, if I have DeepSeek, if I can be much more efficient, do I need these young people any more?'' Ngai said. Zhu Min, a former deputy governor of the People's Bank of China and former deputy managing director of the International Monetary Fund, said the Chinese government should formulate more macroeconomic policies to build a solid social safety net – from healthcare to retirement pensions – to make sure people feel it is safe to spend on consumption. The job market would be another top priority for Beijing, Zhu said, adding that it should make sure that individual incomes grow in line with economic growth. We must address deep-seated structural challenges hindering the domestic cycle by advancing comprehensive reform and opening up In a speech in Tianjin on Wednesday, Premier Li Qiang pledged that China would become a 'consumption powerhouse' capable of fuelling domestic and global growth. Qiushi, the Communist Party's theoretical journal, said in a commentary piece published on Thursday that China should enhance the vitality and reliability of its domestic economic circulation amid rising external uncertainty. 'Strengthening the domestic economic cycle is both a development and a reform issue,' it said. 'We must address deep-seated structural challenges hindering the domestic cycle by advancing comprehensive reform and opening up, improving institutional mechanisms, and refining policy frameworks to provide sustained momentum for domestic circulation.' To tackle mismatches between supply and demand, China will enhance long-term mechanisms to expand consumption and foster a market-driven endogenous growth mechanism for effective investment, it added. 'Insufficient consumer demand remains a major constraint on the domestic economic cycle,' it said. 'We must tap into potential to boost consumption, promote the upgrading of bulk consumption, unleash the potential of service consumption, and amplify the spillover effects of emerging consumption.' Qiushi said Beijing should also spare no effort to stabilise employment by supporting businesses in retaining jobs and expanding employment opportunities across all sectors, particularly in services, with a focus on addressing the employment needs of university graduates, migrant workers and other key groups. - SOUTH CHINA MORNING POST
Malaysian Reserve
2 hours ago
- Malaysian Reserve
TAILG Returns to Jakarta Fair, Deepens Footprint in Indonesia
JAKARTA, Indonesia, June 30, 2025 /PRNewswire/ — On June 19, Indonesia's largest comprehensive exhibition, Jakarta Fair, officially opened at JIExpo in Jakarta. TAILG showcased 11 products and launched on-site test ride experiences, standing out as one of the most prominent two-wheeled electric mobility brands at the expo. User-Oriented, Built for Local Preferences Jakarta Fair Kemayoran runs from June 19 to July 13 at JIExpo in Jakarta, with over 2,550 companies exhibiting across 1,550 booths. The event is expected to generate over 7.5 trillion IDR in transactions. As a global leader in electric two- and three-wheel vehicles, TAILG began localizing operations in Indonesia in 2023. Based on local user needs and preferences, TAILG presented 11 key products at this expo, showcasing strong long range capabilities. The GF52, TAILG's flagship long range model, features a full-coverage airplane-style handlebar, a top speed of 55 km/h, smart cruise control, and a convenient reverse function—making it a popular choice for commuters. Recently, influencer KAYE (TikTok: daffakaye) tested the model in Jakarta traffic, achieving an impressive 102 km on a single charge. The video gained over a million likes and views online. The X51-M, with its mech-style design and lightweight frame, offers a max range of 65 km. Since its launch earlier this year, it has been widely favored by students. Moreover, female-oriented models like GR51, GR52, GE55, and GALAXY EB, boasting eye-catching designs, comfortable seats, and user-friendly handling, perfectly meet the dual demands of practicality and comfort for moms. These features have attracted numerous female users to test-ride on-site. Meanwhile, simple electric models such as JS31, JY32, and JY36, with their lightweight and safe designs, have proven popular among students. Rooted in Indonesia, Committed to Deepening Local Development Since the brand went overseas, TAILG has regarded Indonesia and Vietnam as important benchmark markets for the globalization strategy. Based in Indonesia and radiating to Southeast Asia, TAILG continues to promote localization. In 2024, TAILG opened its office and flagship showroom in Tangerang, followed by the launch of its local factory. It has now established a fully localized system covering R&D, manufacturing, and sales. Centered on Java Island, TAILG has built a sales and service network across major cities, with over 200 branded stores. To further enhance supply chain efficiency and improve local service capacity, TAILG has built an integrated manufacturing base in Indonesia that includes assembly, quality inspection, testing, and logistics. The base follows international quality standards and is equipped with advanced production lines and a comprehensive quality control system to ensure high product quality and efficient delivery. As TAILG expands globally, it continues to partner with world-class brands to offer users smarter and more advanced long range products. As the first electric vehicle brand to form a global strategic partnership with BYD, TAILG is actively introducing BYD's small-capacity blade battery solutions, known for their high safety, long life, and strong performance. Rooted in Indonesia and expanding globally, TAILG's strength in products and branding has been widely recognized by users at the JFK Expo. In the future, TAILG will continue to strengthen its long range product lineup, build a strong reputation for endurance performance, and bring Indonesian users a greener, more convenient, and safer riding experience. YouTube video link:
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ — Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology. 'Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies,' said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. 'We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide.' Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC At the core of Innovent's oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms. 'We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm,' said Dr. Zhou Hui, SVP of Innovent Oncology R&D. 'Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide.' Global R&D Roadmap: a Clear, Stepwise Development Strategy Innovent's pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages: Next-gen IO + Chemotherapy: to redefine the IO cornerstone Next-gen IO + mAb-ADC / bispecific ADC: to cover expansive tumor types and treatment lines Next-gen IO + Dual-Payload ADC (dpADC): to unlock full potential of IO+ ADC synergy, and reshape cancer treatment Currently its oncology pipeline features nearly 10 next-generation molecules in global development, with multi-regional trials actively underway in the U.S., EU, and Asia. The company also continues to invest in global R&D infrastructure, supported by R&D hubs in Shanghai and San Francisco and antibody and ADC manufacturing capacity exceeding 140,000L. Innovent is rapidly expanding its global innovation footprint, with a 2030 goal to advance at least five pipeline assets into global MRCT Phase 3 trials. Key potential candidates includes: IBI343: innovative CLDN18.2 ADC with site-specific conjugation and a TOPO1 inhibitor payload, demonstrating significant survival benefits in both GC and PDAC IBI363: PD-1/IL-2α-bias fusion protein as next-gen IO to redefine cancer treatment and expand the boundaries of IO responsiveness IBI3009: DLL3 ADC in collaboration with Roche IBI3003: tri-specific T-cell engager targeting BCMA/GPRC5D/CD3 for multiple myeloma IBI3001: EGFR/B7H3 ADC with two synergetic targets covering multiple potential indications IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase IBI363: Next-Gen IO Redefining Cancer Immunotherapy IBI363 is a global first-in-class PD-1/IL-2α-bias fusion protein, featuring a differentiated molecular design and a dual immune activation mechanism. Emerging clinical data strongly support its mechanism of action in reinvigorating and expanding tumor-specific T cells (TSTs). At ASCO 2025, IBI363 demonstrated breakthrough potential in three hard-to-treat tumor types, with a long tailing effect in prolonged survival benefits: Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose cohorts, and benefit observed even in PD-L1 low expressers Later-line CRC (3L+): mOS of 16.1 months in monotherapy and only 17.8% OS events occurred in combination with bevacizumab with 9.4 months follow-up, outperforming historical benchmarks Immune-resistant melanoma (mucosal/acral subtypes): confirmed overall response rate (cORR) 23%, median duration of response (mDoR) 14 months, and median OS 14.7 months, showing unprecedented positive response and a long-lasting immunologic tailing effect With two Breakthrough Therapy Designations from the NMPA CDE, two Fast Track Designations from the FDA, IBI363 is advancing rapidly toward registrational development. The first head-to-head trial vs. pembrolizumab in mucosal and acral melanoma was initiated. Meanwhile, IBI363 is in preparation for registrational trails in IO-treated squamous NSCLC, and third-line MSS colorectal cancer. Additional trails for first-line and other solid tumors also under exploration in ongoing PoC studies. High-Potency, Low-toxicity ADC Platforms Synergizing with IO for Broad Indication Coverage Innovent is rapidly advancing its next-gen ADC pipeline, including: IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L) IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors These programs leverage proprietary payloads and linkers, optimized for lower toxicity and high potency, and are poised to synergize with Innovent's IO agents to address broader and deeper indications. Innovent Academy: R&D Engine to Drive Global Innovation Innovent Academy is the company's discovery engine for driving global innovation. The Academy continues to expand its platforms in IO, ADC, T-cell engagers, and cytokines, firmly establishing its leadership in next-gen oncology discovery and translational science to generate 6–8 novel molecules per year. Specifically, for next-gen IO and next-gen ADC dual upgradation, Innovent Academy focuses on: diversified antitumor mechanisms to integrate TME modulation and optimize IO efficacy; dual targeting approaches to overcome tumor heterogeneity and drug resistance. This framework allows Innovent to systematically escalate efficacy and broaden tumor applicability, laying the foundation for first-in-class and best-in-class combination regimens for cancer treatments. Catalyzing China's Role in Global Oncology Innovation Leading oncology KOLs and principal investigators (PIs) delivered keynote speeches, reflecting on a pivotal moment for China's biotech industry. They emphasized that China's innovation, which is driven by rising translational capabilities, expanding global talent pools, and patient-centric trial execution, has entered a 'Deepseek' moment, one where Chinese-discovered drugs can lead global standards, not just follow them. 'What we're witnessing is a profound shift,' said one keynote speaker. 'Innovent's next-generation IO programs like IBI363, with a clear global-first design, and ADC platforms targeting previously untreatable populations, show that Chinese biotech is poised to influence—not just participate in—the next global oncology paradigm.' The enthusiastic response from investors and KOLs underscores growing confidence in China-originated oncology innovation and reaffirms Innovent's position as it enters a new era of global innovation with a vision to become a global premier biopharmaceutical leader. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
